Direct administration of chemotherapy and other agents into the fourth ventricle of the brain is a novel approach to treating recurrent malignant posterior fossa brain tumors in children. Candidates for this treatment approach include patients with recurrent medulloblastoma, ependymoma, atypical teratoid/rhabdoid tumor, and potentially other neoplasms that originate in the fourth ventricle or elsewhere in the posterior fossa. In this chapter, the authors first explain the rationale for considering fourth ventricular drug infusions in patients with recurrent malignant posterior fossa tumors. We then summarize the results of translational experiments conducted in piglets and non-human primates that demonstrated safety and favorable pharmacokinetics. These translational experiments led to several pilot human clinical trials, and the results of these trials are reviewed. Finally, currently open clinical trials testing infusion of various agents into the fourth ventricle are discussed, and thoughts about potential future directions are shared.
Keyphrases
- clinical trial
- pulmonary artery
- pulmonary hypertension
- endothelial cells
- mitral valve
- young adults
- heart failure
- induced pluripotent stem cells
- congenital heart disease
- coronary artery
- left ventricular
- locally advanced
- phase ii
- randomized controlled trial
- climate change
- squamous cell carcinoma
- cerebral ischemia
- atrial fibrillation
- drug induced
- subarachnoid hemorrhage